Mitsubishi Tanabe to sell Lilly's tirzepatide in Japan

8 July 2022

Japanese drugmaker Mitsubishi Tanabe Pharma (TYO: 4508) is to sell US pharma major Eli Lilly’s (NYSE: LLY) diabetes drug tirzepatide in Japan following an agreement between the companies.

Tirzepatide is a novel once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of the GIP and GLP-1 in-cretins into a single molecule. It represents a new class of medicines being developed for the treatment of type 2 diabetes.

In the USA, tirzepatide won approval from the Food and Drug Administration in May of this year as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is sold under the brand name Mounjaro.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK